Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

HUTCHMED (CHINA) LIMITED

(HCM)
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op HUTCHMED (CHINA) LIMITED
20/01Hutchison China MediTech Doses First Patient in Phase 1 Study to Treat Advanced Solid T..
20/01HUTCHMED CHINA : Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant..
20/01Hutchmed Commences Phase I Trial of Tumor Drug Candidate HMPL-653 in China
20/01Hutchmed Launches Early-Stage Trial Of Cancerous Tumor Treatment In China
20/01Hutchmed Starts Cancer Drug's Phase I Study in China
20/01HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Soli..
20/01HUTCHMED Limited Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malign..
19/01HUTCHMED CHINA : Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Ga..
19/01Hutchmed China to Present Data From Clinical Trial of Colorectal Cancer Treatment at On..
19/01HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastroi..
19/01HUTCHMED Limited Update Analysis of Ongoing International Phase I/Ib Trial of Fruquinti..
18/01TR-1 : Standard form for notification of major holdings - Form 6-K
13/01Chinese Regulators Grant Breakthrough Therapy Designation to Hutchmed's Immune Thromboc..
12/01HUTCHMED Secures Breakthrough Therapy Designation in China for Primary Immune Thrombocy..
12/01HUTCHMED CHINA : Receives Break≠through Therapy Designation in China for HMPL-523 for Trea..
12/01HUTCHMED Limited Receives Breakthrough Therapy Designation in China for HMPL-523 for Tr..
10/01HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..
10/01Hutchmed Launches Phase 1 Trial of HMPL-76 in Patients with Previously Treated B-Cell N..
10/01Hutchmed Starts Early-Stage Trial of Blood Cancer Treatment
10/01Hutchmed China Starts Phase 1 Trial of Non-Hodgkin Lymphoma Treatment in China
10/01HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
10/01HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
03/01HUTCHMED CHINA : Blocklisting Six Monthly Return - Form 6-K
2021Certain American Depositary Shares of HUTCHMED Limited are subject to a Lock-Up Agreeme..
2021Certain Ordinary Shares of HUTCHMED Limited are subject to a Lock-Up Agreement Ending o..
2021HUTCHMED CHINA : Included in FTSE Russell Indexes - Form 6-K
2021Hutchmed Added to FTSE Russell Indexes
2021HUTCHMED LIMITED(SEHK : 13) added to FTSE All-World Index
2021Hutchmed to Join FTSE Global Equity Index From Today, Dec. 20
2021HUTCHMED Included in FTSE Russell Indexes
2021HUTCHMED CHINA : ​ - Form 6-K
2021HUTCHMED CHINA : Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meetin..
2021HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021†ASH†Annual†Meeting
2021Hutchmed Presents Clinical Trials Data for Combination Cancer Treatment
2021HUTCHMED CHINA : Highlights Surufatinib and Toripalimab Combination Clinical Data being Pr..
2021HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Present..
2021US Biotech Firm Sirnaomics Passes Hong Kong Listing Hearing
2021HUTCHMED CHINA : Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fru..
2021Hutchmed Completes Patient Enrollment for Late-Stage Colorectal Cancer Trial
2021Hutchmed Completes Patient Enrollment for Metastatic Colorectal Cancer Drug Trial
2021Hutchmed Completes Patient Enrollment for Global Phase 3 Study of Colorectal Cancer Dru..
2021HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquint..
2021Hutchmed Limited Completes Planned Enrollment of FRESCO-2, A Global Phase III Trial of ..
2021HUTCHMED CHINA : Announces Agreement with NHSA for Continued Inclusion of ELUNATEģ and Add..
2021Hutchmed's Two Cancer Therapies Included in China's Drug Reimbursement List
2021China to Add Hutchmed's Tumor Drug in 2022 National Reimbursement Drug List, Retain Fir..
2021Hutchmed Announces Agreement with China National Healthcare Security Administration for..
2021HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATEģ and Addition..
2021Health Care Stocks Mixed Premarket Wednesday
2021HUTCHMED CHINA : and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYSģ and TAGRISSOģ..
2021Hutchmed, AstraZeneca Begin Phase 3 Lung Cancer Trial in China
2021AstraZeneca, Hutchmed Start Late-Stage Trial of Lung Cancer Combo in China
2021Hutchmed, AstraZeneca Dose First Patient in China Phase III Study of Combination Therap..
2021HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYSģ and TAGRISSOģ Comb..
2021Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now avail..
2021International companies to host live webcasts at Deutsche Bank's Depositary Receipts Vi..
2021HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeti..
2021Hutchmed to Present Cancer Drug Clinical Data at US Hematology Conference
2021HUTCHMED Limited to Present Clinical Data At ASH Annual Meeting
2021HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021†ASH†Annual†Meeti..
2021HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..
2021Hutchmed, AstraZeneca Begin Phase 3 Trial of Drug Combo to Treat Kidney Cancer
2021Hutchmed, AstraZeneca Launch Late-Stage Study of Kidney Cancer Combo Therapy
2021Hutchmed, AstraZeneca Dose First Patient in Global Phase III Study of Combination Thera..
2021HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combi..
2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..
2021Hutchmed Starts Late-Stage Autoimmune Drug Trial in China
2021Hutchmed Begins Late-Stage Study of Platelet Disorder Drug in China
2021Hutchmed Doses First Patient in China Phase III Study of Autoimmune Disorder Therapy
2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune†Thro..
2021HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thro..
2021HUTCHMED CHINA : Grant of Awards under Long Term Incentive Plan - Form 6-K
2021HUTCHMED CHINA : Announces Closing of Divestment of Non-Core OTC Joint Venture (Form 6-K)
2021HUTCHMED CHINA : Combination Therapies Show Potential Antitumor Activities in Separate Pha..
2021HUTCHMED CHINA : Completes $169 Million Sale of Over-the-Counter Drug JV Business
1  2  3  4  5Volgende
Volgende evenement op HUTCHMED (CHINA) LIMITED
14/03/22
Komende gebeurtenissen in de sector